ClinicalTrials.gg
CompletedNCT01947777DDIUpdated Mar 17, 2021

Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145

A Phase 1 interventional study of IPI-145 and Rifampin in Healthy, sponsored by SecuraBio. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by SecuraBio · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To evaluate the effect of rifampin, a cytochrome P450 3A (CYP3A) inducer, on the pharmacokinetics (PK) of IPI-145; to assess the safety and tolerability of IPI-145 when administered with rifampin in healthy subjects

Read the detailed description
  • In Treatment Period 1, subjects will receive a single 25 mg oral dose of IPI-145
  • In Treatment Period 2, on Days 3-9, the same subjects will receive once daily (QD) oral doses of 600 mg rifampin; on Day 9, subjects will receive a single oral dose of 25 mg IPI-145 concomitantly administered with 600 mg of rifampin
02

Conditions studied

  • Healthy

Keywords

  • Phase 1
  • Healthy subjects
  • DDI
  • CYP3A
03

In context

Lead sponsor

SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men or women of non- between 18-50 years of age
  • (BMI): 18.0 - 32.0 kg/m2
  • In good health, determined by no findings from clinical evaluations
  • Provided written prior to any study specific procedures

Exclusion criteria

Exclusion Criteria:

  • Women of
  • Evidence of medical conditions
  • History of gastrointestinal disease or surgery that may affect drug absorption
  • Positive or indeterminate Tuberculosis -spot test at screening
  • Any active infection at the time of screening or admission
  • Consumption of any nutrients known to modulate cytochrome P450 enzyme activity within 14 days prior to administration of study drug, during the study, and until after discharge
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters (AUC) of IPI-145 and its metabolite, IPI-656

    Time frame: Over 48 hours

  2. Pharmacokinetic parameters (Cmax) of IPI-145 and its metabolite, IPI-656

    Time frame: Over 48 hours

  3. Pharmacokinetic parameters (t1/2) of IPI-145 and its metabolite, IPI-656

    Time frame: Over 48 hours

  4. Plasma concentrations of IPI-145 and its metabolite, IPI-656

    Time frame: Over 48 hours

Secondary outcomes

  1. Incidence of adverse events following administration of IPI-145, rifampin, and the combination.

    Safety Findings

    Time frame: 2 weeks

07

Study locations

1 site
  • PRA International, Inc
    Lenexa, Kansas 66219, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Nov 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2013
First posted
Sep 20, 2013
Start
Oct 2013
Primary completionActual
Nov 2013
CompletionActual
Dec 2013
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01947777
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Sep 20, 2013
Start date
Oct 2013
Primary completion
Nov 2013
Completion
Dec 2013
Last update
Mar 17, 2021

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Duvelisib · Rifampin

Start the discussion